DFFN Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
Company profile
Ticker
DFFN
Exchange
Website
CEO
Robert J. Cobuzzi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FERIS INTERNATIONAL, INC., RestorGenex Corp, Stratus Media Group, Inc, TITAN MOTORCYCLE CO OF AMERICA INC
SEC CIK
Corporate docs
IRS number
300645032
DFFN stock data
()
News
12 Health Care Stocks Moving In Thursday's After-Market Session
18 Feb 21
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
18 Feb 21
Stocks That Hit 52-Week Highs On Wednesday
17 Feb 21
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
17 Feb 21
12 Health Care Stocks Moving In Tuesday's Intraday Session
16 Feb 21
Press releases
Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
4 Mar 21
Diffusion Pharmaceuticals Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock
18 Feb 21
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock
17 Feb 21
Thinking about buying stock in Diffusion Pharmaceuticals, Northern Dynasty Minerals, Zomedica, Sundial Growers, or Citius Pharmaceuticals?
17 Feb 21
Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?
16 Feb 21
Investment data
Securities sold
Number of investors
Calendar
12 Nov 20
6 Mar 21
31 Dec 21
Financial summary
Quarter (USD) |
Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.91M | 21.91M | 21.91M | 21.91M | 21.91M | 21.91M |
Cash burn (monthly) | 1.22M | (positive/no burn) | 1.76M | 1.24M | 1.17M | 1.03M |
Cash used (since last report) | 6.32M | n/a | 9.13M | 6.47M | 6.08M | 5.33M |
Cash remaining | 15.59M | n/a | 12.78M | 15.44M | 15.83M | 16.58M |
Runway (months of cash) | 12.8 | n/a | 7.3 | 12.4 | 13.5 | 16.2 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 21 | William Karl Hornung | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 80,069 | 88.88K | 80,069 |
1 Mar 21 | William Karl Hornung | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 122,771 | 136.28K | 122,771 |
1 Mar 21 | William Robert Elder | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 62,522 | 69.4K | 62,522 |
1 Mar 21 | William Robert Elder | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 87,684 | 97.33K | 87,684 |
1 Mar 21 | Christopher D Galloway | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 81,537 | 90.51K | 81,537 |
1 Mar 21 | Christopher D Galloway | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 27,180 | 30.17K | 27,180 |
1 Mar 21 | Cobuzzi Robert Joseph Jr. | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 161,139 | 178.86K | 161,139 |
1 Mar 21 | Cobuzzi Robert Joseph Jr. | Stock Option Common Stock | Grant | Aquire A | No | No | 1.11 | 53,713 | 59.62K | 53,713 |
17 Nov 20 | William Robert Elder | Common Stock | Buy | Aquire P | No | No | 0.63 | 5,000 | 3.15K | 15,000 |
16 Nov 20 | William Robert Elder | Common Stock | Buy | Aquire P | No | No | 0.67 | 10,000 | 6.7K | 10,000 |
Institutional ownership Q4 2020
4.8% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 21 |
Opened positions | 5 |
Closed positions | 9 |
Increased positions | 3 |
Reduced positions | 4 |
13F shares |
Current |
---|---|
Total value | 3.86M |
Total shares | 4.85M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Renaissance Technologies | 2.83M | $2.25M |
BLK Blackrock | 830.47K | $660K |
Vanguard | 393.23K | $312K |
Geode Capital Management | 255.69K | $203K |
NTRS Northern Trust | 107.89K | $86K |
Two Sigma Investments | 106.34K | $85K |
Fan Yu | 89.85K | $71K |
Two Sigma Advisers | 69.7K | $55K |
Raymond James Financial Services Advisors | 40K | $32K |
Advisor | 29.48K | $24K |
Financial report summary
?Competition
CurisManagement Discussion
- We recognized $3.1 million in R&D expenses during the three months ended September 30, 2020 compared to $1.7 million during the three months ended September 30, 2019. A significant portion of this increase was attributable to R&D expenses related to the 100-303 COVID Trial initiated in September 2020 and our related ramp-up, including a $0.4 million increase in manufacturing costs and a $1.0 million increase in clinical trial and other R&D expenses. The overall increase in R&D expense also includes a $0.1 million increase in costs associated with the PHAST Trial, primarily costs related to winding down the trial. These increases in R&D expenses were offset in part by a $0.1 million decrease in R&D related salaries, wages and stock-based compensation expense.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accomplish, adjudication, adjunctive, adjunctively, administered, afflicted, Affordable, air, allosteric, ambulance, analyzed, appointed, arrangement, artery, ascending, attempt, avoiding, belief, Bioconnect, biopharmaceutical, Biotech, blocked, bonding, breakdown, breathing, broad, Bucharest, cell, Christopher, claudication, Cobuzzi, complex, complicated, complicating, complication, concept, Conference, confirmed, contributor, Corona, counsel, coupled, COVID, CRO, cumulative, daily, dense, detail, die, director, Education, efficient, Elder, employee, encountered, endpoint, energy, enhance, equipment, evenly, eventually, excessive, expansion, expediting, experimental, explained, explicitly, extension, extracorporeal, factor, final, frequency, fully, Galloway, greater, HC, heading, high, Hollingsworth, hydrogen, hyperoxia, identification, implied, infiltration, innovative, intermittent, intractable, invalidation, ischemia, Jane, knowledge, leadership, Litigation, lt, matrix, membrane, metabolic, modification, NOL, onset, opportunistic, ordinary, Orphan, outsource, oversee, ownership, oximetry, peripheral, persistence, pharmacodynamic, pharmacokinetic, political, postponed, predecessor, preferentially, presidential, Prevention, prioritizing, proceed, produce, progressing, promulgated, proof, prospectively, publicly, pulse, put, quantify, Reconciliation, red, Reform, regimen, relevant, remeasured, repeal, replacement, resignation, responded, retirement, Robert, Romania, room, Secondary, separation, sequential, Showcase, stockholder, streamline, subgroup, subsidized, successfully, summer, supplemental, taxable, team, tolerability, tolerable, topline, toxicity, Trail, unamended, Union, unknown, variety, ventilation, vessel, virtual, warrent, water, William, wind, winding
Removed:
administrative, assumed, bring, bulk, cardiovascular, cellular, Codification, commencement, commercial, competing, continuing, cooperation, criteria, crocetinate, cut, dependent, deprivation, DSMB, emergency, entering, exploring, forward, growth, hire, improving, inaccurate, inherent, label, met, move, multiforme, NDA, neurodegenerative, omitted, open, permission, practice, PreHospital, promote, protect, randomization, ranging, reader, safely, scope, selectively, sodium, spend, strong, survival, test, tested, transcrocetinate, treated, tumor, type, UCLA, University, unmet, untreated, utility
Financial reports
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
17 Mar 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
19 Mar 19
10-Q
2018 Q3
Quarterly report
13 Nov 18
10-Q
2018 Q2
Quarterly report
10 Aug 18
Current reports
8-K
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
18 Feb 21
8-K
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
16 Feb 21
8-K
Note Regarding Forward-looking Statements
12 Feb 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Jan 21
8-K
Regulation FD Disclosure
8 Jan 21
8-K
Regulation FD Disclosure
14 Dec 20
8-K
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
12 Nov 20
8-K
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
20 Oct 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Oct 20
8-K
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
25 Sep 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Feb 21
FWP
Free writing prospectus
11 Feb 21
FWP
Free writing prospectus
11 Feb 21
424B5
Prospectus supplement for primary offering
11 Feb 21
424B2
Prospectus for primary offering
2 Oct 20
S-3
Shelf registration
25 Sep 20
424B3
Prospectus supplement
8 Jun 20
S-1/A
IPO registration (amended)
3 Jun 20
S-1
IPO registration
29 May 20
D
$750K in options / securities to be acquired, sold $750K, 4 investors
27 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
19 Apr 18
DEF 14A
Definitive proxy
17 Sep 17
PRE 14A
Preliminary proxy
7 Sep 17
Other
EFFECT
Notice of effectiveness
5 Oct 20
CORRESP
Correspondence with SEC
29 Sep 20
UPLOAD
Letter from SEC
28 Sep 20
EFFECT
Notice of effectiveness
11 Jun 20
CORRESP
Correspondence with SEC
2 Jun 20
UPLOAD
Letter from SEC
1 Jun 20
EFFECT
Notice of effectiveness
30 Dec 19
CORRESP
Correspondence with SEC
22 Dec 19
UPLOAD
Letter from SEC
22 Dec 19
EFFECT
Notice of effectiveness
14 Nov 19
Ownership
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
4 Mar 21
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
4 Mar 21
4
Diffusion Pharmaceuticals / CHRISTOPHER D GALLOWAY ownership change
4 Mar 21
4
Diffusion Pharmaceuticals / William Karl Hornung ownership change
4 Mar 21
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
18 Nov 20
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
18 Nov 20
4
Diffusion Pharmaceuticals / CHRISTOPHER D GALLOWAY ownership change
21 Oct 20
3
Diffusion Pharmaceuticals / CHRISTOPHER D GALLOWAY ownership change
21 Oct 20
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
14 Oct 20
3
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
14 Oct 20
Reddit threads
Best day I've had in a month! What should I do?
5 Mar 21
📈What is everyone buying on March 1st📈
28 Feb 21
Let's please remind people that they can lose everything on GME
25 Feb 21
Daily Plays - February 24, 2021
24 Feb 21
Guys this does not happen by accident. We are due for correction. Be patient and average down if you have buying power. We love cheapies! If you have no buying power just wait. You will be paid soon enough.
23 Feb 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - February 23, 2021
22 Feb 21
Anyone else having nothing but red this week or have I just made poor life choices?
18 Feb 21
Daily Plays - February 18, 2021
18 Feb 21
Daily Plays - February 17, 2021
17 Feb 21
DFFN DD and possible catalysts
16 Feb 21